-
Something wrong with this record ?
Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network
CY Cheah, A George, E Gine, A Chiappella, HC Kluin-Nelemans, W Jurczak, K Krawczyk, H Mocikova, P Klener, D Salek, J Walewski, M Szymczyk, L Smolej, RL Auer, DS Ritchie, L Arcaini, ME Williams, M Dreyling, JF Seymour, Mantle Cell Lymphoma Network European
Language English Country Great Britain
Grant support
NT13072
MZ0
CEP Register
NT13201
MZ0
CEP Register
Digital library NLK
Full text - Article
Full text - Article
Source
Source
NLK
Free Medical Journals
from 1996 to 1 year ago
PubMed
23616279
DOI
10.1093/annonc/mdt139
Knihovny.cz E-resources
- MeSH
- Central Nervous System * pathology MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Lymphoma, Mantle-Cell * drug therapy MeSH
- Central Nervous System Neoplasms drug therapy prevention & control secondary MeSH
- Leukocyte Count MeSH
- Survival MeSH
- Antimetabolites, Antineoplastic therapeutic use MeSH
- Retrospective Studies MeSH
- Risk MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Geographicals
- Europe MeSH
BACKGROUND: Central nervous system (CNS) involvement in mantle cell lymphoma (MCL) is uncommon, and the manifestations and natural history are not well described. PATIENTS AND METHODS: We present the data on 57 patients with MCL who developed CNS involvement, from a database of 1396 consecutively treated patients at 14 institutions. RESULTS: The crude incidence of CNS involvement was 4.1%, with 0.9% having CNS involvement at diagnosis. Blastoid histology, B-symptoms, elevated lactate dehydrogenase, Eastern Cooperative Group performance status >=2 and a high Mantle Cell Lymphoma International Prognostic Index score were enriched in the cohort with CNS involvement, and the presence of >=1 of these features defined a high-risk subset (an actuarial risk of CNS involvement 15% at 5 years) in a single-institution subset. The median time to CNS relapse was 15.2 months, and the median survival from time of CNS diagnosis was 3.7 months. The white blood cell count at diagnosis <10.9 x 109/l, treatment of CNS involvement with high-dose anti-metabolites, consolidation with stem cell transplant and achievement of complete response were all associated with improved survival. CONCLUSIONS: In MCL, CNS involvement is uncommon, although some features may predict risk. Once manifest outlook is poor; however, some patients who receive intensive therapy survive longer than 12 months.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19036559
- 003
- CZ-PrNML
- 005
- 20191113143512.0
- 007
- ta
- 008
- 191011s2013 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/annonc/mdt139 $2 doi
- 035 __
- $a (PubMed)23616279
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Cheah CY $u Cheah, C Y. Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia.
- 245 10
- $a Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network / $c CY Cheah, A George, E Gine, A Chiappella, HC Kluin-Nelemans, W Jurczak, K Krawczyk, H Mocikova, P Klener, D Salek, J Walewski, M Szymczyk, L Smolej, RL Auer, DS Ritchie, L Arcaini, ME Williams, M Dreyling, JF Seymour, Mantle Cell Lymphoma Network European
- 520 9_
- $a BACKGROUND: Central nervous system (CNS) involvement in mantle cell lymphoma (MCL) is uncommon, and the manifestations and natural history are not well described. PATIENTS AND METHODS: We present the data on 57 patients with MCL who developed CNS involvement, from a database of 1396 consecutively treated patients at 14 institutions. RESULTS: The crude incidence of CNS involvement was 4.1%, with 0.9% having CNS involvement at diagnosis. Blastoid histology, B-symptoms, elevated lactate dehydrogenase, Eastern Cooperative Group performance status >=2 and a high Mantle Cell Lymphoma International Prognostic Index score were enriched in the cohort with CNS involvement, and the presence of >=1 of these features defined a high-risk subset (an actuarial risk of CNS involvement 15% at 5 years) in a single-institution subset. The median time to CNS relapse was 15.2 months, and the median survival from time of CNS diagnosis was 3.7 months. The white blood cell count at diagnosis <10.9 x 109/l, treatment of CNS involvement with high-dose anti-metabolites, consolidation with stem cell transplant and achievement of complete response were all associated with improved survival. CONCLUSIONS: In MCL, CNS involvement is uncommon, although some features may predict risk. Once manifest outlook is poor; however, some patients who receive intensive therapy survive longer than 12 months.
- 590 __
- $a bohemika - dle Pubmed
- 650 02
- $a dospělí $7 D000328
- 650 02
- $a senioři $7 D000368
- 650 02
- $a senioři nad 80 let $7 D000369
- 650 02
- $a protinádorové antimetabolity $x terapeutické užití $7 D000964
- 650 12
- $a centrální nervový systém $x patologie $7 D002490
- 650 02
- $a nádory centrálního nervového systému $x farmakoterapie $x prevence a kontrola $x sekundární $7 D016543
- 650 02
- $a ženské pohlaví $7 D005260
- 650 02
- $a lidé $7 D006801
- 650 02
- $a počet leukocytů $7 D007958
- 650 12
- $a lymfom z plášťových buněk $x farmakoterapie $7 D020522
- 650 02
- $a mužské pohlaví $7 D008297
- 650 02
- $a lidé středního věku $7 D008875
- 650 02
- $a retrospektivní studie $7 D012189
- 650 02
- $a riziko $7 D012306
- 650 02
- $a přežití $7 D013534
- 650 02
- $a výsledek terapie $7 D016896
- 651 _2
- $a Evropa $7 D005060
- 700 1_
- $a George A
- 700 1_
- $a Gine E
- 700 1_
- $a Chiappella A
- 700 1_
- $a Kluin-Nelemans HC
- 700 1_
- $a Jurczak W
- 700 1_
- $a Krawczyk K
- 700 1_
- $a Móciková, Heidi, $d 1964- $7 mzk2009517509
- 700 1_
- $a Klener P
- 700 1_
- $a Šálek, David $7 xx0211647
- 700 1_
- $a Walewski J
- 700 1_
- $a Szymczyk M
- 700 1_
- $a Smolej, Lukáš $7 xx0101489
- 700 1_
- $a Auer RL
- 700 1_
- $a Ritchie DS
- 700 1_
- $a Arcaini L
- 700 1_
- $a Williams ME
- 700 1_
- $a Dreyling M
- 700 1_
- $a Seymour JF
- 700 1_
- $a European Mantle Cell Lymphoma Network
- 773 0_
- $t Annals of Oncology $g Roč. 24, č. 8 (2013), s. 2119-2123 $p Ann Oncol $x 0923-7534 $w MED00000432
- 773 0_
- $p Ann Oncol $g 24(8):2119-23, 2013 Aug
- 910 __
- $a ABA008 $b sig $y 4 $z 0
- 990 __
- $a 20191011130414 $b ABA008
- 991 __
- $a 20191113143749 $b ABA008
- 999 __
- $a ok $b bmc $g 1453867 $s 1075125
- BAS __
- $a 3
- BMC __
- $a 2013 $b 24 $c 8 $d 2119-2123 $x MED00000432 $i 0923-7534 $m Annals of oncology
- GRA __
- $a NT13072 $p MZ0
- GRA __
- $a NT13201 $p MZ0
- LZP __
- $a NLK 2019/lp